

Neurosteroidy - Neuropatická bolest (NP)

Fáze vývoje technologie

Preklinické testy

Status IP ochrany

Kudova et al.: Amphiphilic Compounds with Neuroprotective Properties. EP3260462 A, EP3260462 A, CA 2957906 A, JP 2017-511948, US 15/506318, AU 2015309371

Strategie pro hledání partnera

Licencování, Spin-off, Spolupráce

STEROIDS for Neuropathic Pain Treatment

The Pain Pathway
Glutamate and its receptors represent a major neurotransmitter system at the first spinal synapse. NMDA antagonists are conceivable analgesics, clinically proven as quite efficacious, however, due to the presence of NMDA receptors in the whole CNS, systemic administration of NMDA antagonists brings a number of adverse side effects (memory impairment, psychomotoric changes, ataxia, disturbances of motor coordination, sensation etc.). Our proprietary, specifically designed steroidal molecules act as ALLOSTERIC MODULATORS of NMDA receptor with no observed side effects at the therapeutic dosing level.

Efficacy
Preclinical studies: PPRN Model, PPRN Effect on Mechanical Pain Threshold after Chronic Dosing, Steroid-induced Peripheral Neuropathy (SIPN) Model.

Safety
Dose-toxicity studies, Activity Test - sedation 100 mg/kg.

Pharmacokinetics
PK study after single IP dosing of 0.2 and 10 mg/kg MS-225 in mice, Comparative PK study (2 to 6 dosing of MS-225 in rat (p.o)).

Available ADME data

- No CYP 450 inhibition
- Modest mucronal stability in rat, low in human
- Low toxicity in acute toxicity studies
- LogP=8
- CSF:Blood Safety Study on 40 selected receptors and enzymes
- No binding to MDR1
- Primary MTD in 100 mg/kg

Preclinical Plan

- Design of new molecules
- Preclinical studies: Dose-toxicity, Pain, Neuropathy, Neuroprotection
- Lead and non-lead selection based on Preclinical Assessment
- Preclinical studies in Neuropathic Pain Model
- ADME studies and CSF:Blood of active, Peripheral: Spinal: Central
- Lead selection

IP status

- EP3260462 A
- EP3260462 B
- US 2017/024258
- CA 2957906 A
- JP 2017/511948
- AU 2015309371

IOCB Tech

Project Manager Contact
John Salko, Ph.D.
IOCB Tech
1000 University Ave.
Berkeley, CA 94720
USA
jsalko@iocbtech.com

This is a project of the Center for Development of Original Drugs (CDOD) with the financial support of the Ministry of Health of the Czech Republic.

Motivace

The NP market is rife with unmet needs. The main classes of drugs used in the treatment of NP have traditionally consisted of antidepressants, anticonvulsants, opioid analgesics, and topical analgesics. Although many of the available drugs offer some degree of efficacy in terms of pain relief, there still remains vast room for improvement in efficacy, safety, drug delivery, and dosing convenience. Market size 2017 is about 3 bil. USD, CAGR 3%

Popis

Neurosteroids act as multi-target allosteric modulators of various neuro-receptors. Among others, the NMDA receptor modulators influence the ion flow in synapses. Allosteric NMDAr modulators do not reveal typical adverse effects (in animal models) like dizziness, nausea, somnolence or cognitive difficulties as the current therapeutics often acting as Ca or Na channel blockers. MS-225 shows inhibitory effect at micromolar concentrations. However, there are other receptor families involved in the pain perception. This might be the dominant mode of action and as such is a subject of further research and a new application for extended patent protection. Besides the NP, some steroidal analogues has proven its efficacy in epilepsy or neuroprotection models.

Komerční využití

If the clinical trials confirm its efficacy and low adverse effects, the molecule can easily acquire 10-30% of the market counting from 300 mil. to 1 bil. USD.

Institute

IOCB Tech

Ústav organické chemie a
biochemie AV ČR, v.v.i.